Cargando…

Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus

BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with depressive symptoms, which affect prognosis and quality of life. We investigated the antidepressant effects of n-3 fatty acids (n-3FAs) monotherapy (without conventional antidepressants) for T2DM patients with mild to moderate d...

Descripción completa

Detalles Bibliográficos
Autores principales: MAZAHERIOUN, Maryam, SAEDISOMEOLIA, Ahmad, JAVANBAKHT, Mohammad Hassan, KOOHDANI, Fariba, ZAREI, Mahnaz, ANSARI, Samaneh, KHOSHKHOO BAZARGANI, Fatemeh, DJALALI, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996325/
https://www.ncbi.nlm.nih.gov/pubmed/29900143
_version_ 1783330829485735936
author MAZAHERIOUN, Maryam
SAEDISOMEOLIA, Ahmad
JAVANBAKHT, Mohammad Hassan
KOOHDANI, Fariba
ZAREI, Mahnaz
ANSARI, Samaneh
KHOSHKHOO BAZARGANI, Fatemeh
DJALALI, Mahmoud
author_facet MAZAHERIOUN, Maryam
SAEDISOMEOLIA, Ahmad
JAVANBAKHT, Mohammad Hassan
KOOHDANI, Fariba
ZAREI, Mahnaz
ANSARI, Samaneh
KHOSHKHOO BAZARGANI, Fatemeh
DJALALI, Mahmoud
author_sort MAZAHERIOUN, Maryam
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with depressive symptoms, which affect prognosis and quality of life. We investigated the antidepressant effects of n-3 fatty acids (n-3FAs) monotherapy (without conventional antidepressants) for T2DM patients with mild to moderate depressive symptoms. METHODS: A 10-wk, placebo-controlled, double-blind, parallel-group (1:1 ratio) randomized trial of n-3FAs (2700 mg/day EPA: DHA ratio=2) versus placebo in 88 Iranian diabetic patients with mild to moderate depression based on Beck Depression Inventory II (BDI-II-PERSIAN) was conducted. This study started from July 2014 to January 2015 in Tehran University of Medical Sciences, Tehran, Iran. The primary event was defined as worsened, non-changed, or inconsiderably improved depression (<5 unit decrease in BDI-II-PERSIAN depression scores after treatment) (ClinicalTrials.gov Identifier: NCT02261545). RESULTS: Randomly, 44 T2DM patients were treated with n-3FAs supplements and 44 cases received placebo (three patients discontinued). n-3FAs could significantly protect patients against the aforesaid event and exhibit satisfactory prevention (number needed to treat with 95% confidence interval: 2.52, 1.71–4.74). No serious adverse reactions were reported. CONCLUSION: n-3FAs supplementation had significant antidepressant effects in T2DM patients with mild to moderate depressive symptoms, not confounded by metabolic factors and disease duration.
format Online
Article
Text
id pubmed-5996325
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-59963252018-06-13 Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus MAZAHERIOUN, Maryam SAEDISOMEOLIA, Ahmad JAVANBAKHT, Mohammad Hassan KOOHDANI, Fariba ZAREI, Mahnaz ANSARI, Samaneh KHOSHKHOO BAZARGANI, Fatemeh DJALALI, Mahmoud Iran J Public Health Original Article BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with depressive symptoms, which affect prognosis and quality of life. We investigated the antidepressant effects of n-3 fatty acids (n-3FAs) monotherapy (without conventional antidepressants) for T2DM patients with mild to moderate depressive symptoms. METHODS: A 10-wk, placebo-controlled, double-blind, parallel-group (1:1 ratio) randomized trial of n-3FAs (2700 mg/day EPA: DHA ratio=2) versus placebo in 88 Iranian diabetic patients with mild to moderate depression based on Beck Depression Inventory II (BDI-II-PERSIAN) was conducted. This study started from July 2014 to January 2015 in Tehran University of Medical Sciences, Tehran, Iran. The primary event was defined as worsened, non-changed, or inconsiderably improved depression (<5 unit decrease in BDI-II-PERSIAN depression scores after treatment) (ClinicalTrials.gov Identifier: NCT02261545). RESULTS: Randomly, 44 T2DM patients were treated with n-3FAs supplements and 44 cases received placebo (three patients discontinued). n-3FAs could significantly protect patients against the aforesaid event and exhibit satisfactory prevention (number needed to treat with 95% confidence interval: 2.52, 1.71–4.74). No serious adverse reactions were reported. CONCLUSION: n-3FAs supplementation had significant antidepressant effects in T2DM patients with mild to moderate depressive symptoms, not confounded by metabolic factors and disease duration. Tehran University of Medical Sciences 2018-04 /pmc/articles/PMC5996325/ /pubmed/29900143 Text en Copyright© Iranian Public Health Association & Tehran University of Medical Sciences http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
MAZAHERIOUN, Maryam
SAEDISOMEOLIA, Ahmad
JAVANBAKHT, Mohammad Hassan
KOOHDANI, Fariba
ZAREI, Mahnaz
ANSARI, Samaneh
KHOSHKHOO BAZARGANI, Fatemeh
DJALALI, Mahmoud
Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title_full Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title_fullStr Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title_full_unstemmed Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title_short Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus
title_sort long chain n-3 fatty acids improve depression syndrome in type 2 diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996325/
https://www.ncbi.nlm.nih.gov/pubmed/29900143
work_keys_str_mv AT mazaheriounmaryam longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT saedisomeoliaahmad longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT javanbakhtmohammadhassan longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT koohdanifariba longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT zareimahnaz longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT ansarisamaneh longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT khoshkhoobazarganifatemeh longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus
AT djalalimahmoud longchainn3fattyacidsimprovedepressionsyndromeintype2diabetesmellitus